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Jembrana disease virus (JDV) is a bovine lentivirus genetically similar to bovine immunodeficiency virus; it
causes an acute and sometimes fatal disease in infected animals. This virus carries a very potent Tat that can
strongly activate not only its own long terminal repeat (LTR) but also the human immunodeficiency virus
(HIV) LTR. In contrast, HIV Tat cannot reciprocally activate the JDV LTR (H. Chen, G. E. Wilcox, G.
Kertayadnya, and C. Wood, J. Virol. 73:658–666, 1999). This indicates that in transactivation JDV Tat may
utilize a mechanism similar to but not the same as that of the HIV Tat. To further study the similarity of JDV
and HIV tat in transactivation, we first tested the responses of a series of HIV LTR mutants to the JDV Tat.
Cross-transactivation of HIV LTR by JDV Tat was impaired by mutations that disrupted the HIV type 1
transactivation response element (TAR) RNA stem-loop structure. Our results demonstrated that JDV Tat,
like HIV Tat, transactivated the HIV LTR at least partially in a TAR-dependent manner. However, the
sequence in the loop region of TAR was not as critical for the function of JDV Tat as it was for HIV Tat. The
competitive inhibition of Tat-induced transactivation by the truncated JDV or HIV Tat, which consisted only
of the activation domain, suggested that similar cellular factors were involved in both JDV and HIV Tat-
induced transactivation. Based on the one-round transfection assay with HIV tat mutant proviruses, the
cotransfected JDV tat plasmid can functionally complement the HIV tat defect. To further characterize the
effect of JDV Tat on HIV, a stable chimeric HIV carrying the JDV tat gene was generated. This chimeric HIV
replicated in a T-cell line, C8166, and in peripheral blood mononuclear cells, which suggested that JDV Tat can
functionally substitute for HIV Tat. Further characterization of this chimeric virus will help to elucidate how
JDV Tat functions and to explain the differences between HIV and JDV Tat transactivation.
Lentiviruses are a group of retroviruses usually associated
with slowly developing diseases with a number of different
clinical manifestations of infection in different virus-host sys-
tems (13, 14). For example, human immunodeficiency virus
(HIV) causes immunodeficiency and ultimately leads to the
death of infected patients several years after infection (14). In
contrast, a recently characterized bovine lentivirus, Jembrana
disease virus (JDV), causes an acute disease in infected ani-
mals after a short incubation period (7, 60, 61). It is probable
that an understanding of the differences in molecular mecha-
nisms involved in the pathogenesis of different lentiviruses will
provide important insights into methods of controlling lentivi-
rus-induced diseases such as AIDS.
The genomes of all lentiviruses contain three major struc-
tural genes, gag, pol, and env, as well as several accessory and
regulatory genes flanked by the two long terminal repeats
(LTRs) (14). In HIV, at least six accessory and regulatory
genes, tat, rev, nef, vif, vpr, and vpu, have been identified pre-
viously (14). Studies of these accessory genes have suggested
that most of them are involved in viral replication and patho-
genesis (19, 33, 39, 42, 44, 46, 57). The HIV tat gene has been
extensively studied and is an essential determinant of viral
replication and the pathogenesis of infection (3, 4, 12, 16, 18,
31, 58, 62). Tat is a potent transactivator for HIV gene expres-
sion (3, 4) and has also been shown to modulate the expression
of cellular genes, such as those for major histocompatibility
complex class I (30), tumor necrosis factor alpha (8, 48), in-
terleukin-2 (IL-2) (59), IL-6 (53), and several extracellular
matrix proteins (54). The Tat protein is released from HIV
type 1 (HIV-1)-infected cells and can be detected in sera of
HIV-1-infected individuals (24). Extracellular Tat may be in-
volved in suppression of the host immune response and cellu-
lar disorders associated with AIDS pathology (2, 23). Tat can
synergize with cellular basic fibroblast growth factor and may
be involved in the induction of Kaposi’s sarcoma lesions (6, 22,
23). In addition, Tat may participate in the induction of apo-
ptosis in lymphocytes and contribute to the depletion of the
CD41 T cells in AIDS patients (40, 43, 58). The role of Tat in
HIV pathogenesis may not be limited to its transactivation
function (31). Tat may also play a role in viral replication.
Indeed, Tat has recently been shown to be required for effi-
cient HIV-1 reverse transcription (27, 28, 29). Thus, there is
ample evidence to suggest that the HIV Tat is a pleiotropic
protein, but how Tat is involved in HIV pathogenesis is still an
enigma. Further understanding of the molecular basis for how
Tat plays a role in viral replication and viral pathogenesis
would be of fundamental importance to our understanding of
lentiviruses.
JDV is a recently identified lentivirus (9, 10, 61) related to
bovine immunodeficiency virus (BIV), but in contrast to BIV,
it causes an acute disease atypical of most lentivirus infections
(7, 60, 61). JDV infection of cattle can lead to death of the
animal within 1 to 2 weeks (60, 61). The virus replicates to
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FIG. 1. Effects of HIV TAR mutations on the transactivation of HIV LTR by both JDV Tat and HIV Tat. (A) Schematic presentation of the HIV LTR and mutant
TAR constructs which were described in detail previously (25). TARCAT represents the wild-type LTR. All other modifications are as follows: Mod1CAT, 4-base
deletion (GAUC) in the bulge region; Mod2CAT, 5-base insertion (CGAUC) in the bulge region; Mod3CAT, 2-base substitution (GG mutated to UU) in the loop
region; Mod4CAT, 4-base insertion (CUCG) between the bulge and the upper stem-loop region; Mod5CAT, 5-base insertion (AAAAA) in the loop region; Mod6CAT,
35-base deletion, including the bulge and the downstream sequences; Mod7CAT, 8-base substitution (UUCCCGGG) in the lower stem-loop region. The shaded letters
represent the deleted residues, and the boldface letters represent the substituted residues. (B) A 0.05-mg amount of LTR mutants was cotransfected with 0.5 mg of either
pUC-Jtat or pUC-Htat. At 48 h posttransfection, cell lysates were collected and subjected to bicinchoninic acid assay. By using the same amount of total cellular protein,
the expressed CAT protein in the transfected cell lysate was measured with the CAT ELISA kit as described in Materials and Methods. The relative CAT concentrations
(conc.) shown in the figure represent the results from at least three independent experiments. The number above each bar represents fold activation for each LTR,
and the transactivation fold was obtained by dividing the amount of CAT protein in the presence of Tat protein by the amount of CAT in the absence of Tat (11).
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extremely high titers in infected animals, and since Tat plays an
important role in viral replication, we hypothesized that JDV
encodes a potent transactivator, Tat, responsible for its robust
replication activity in vivo. In previous studies, we have shown
that JDV encodes a Tat that can strongly activate not only the
JDV LTR but also the LTRs of other lentiviruses, including
the HIV LTR (11). Other than BIV Tat, JDV Tat is the only
other nonprimate viral Tat to effectively transactivate the HIV
LTR (41), which implies that similar mechanisms may be
shared between HIV and the bovine lentivirus Tat proteins. It
also suggests that bovine lentiviruses may have a close evolu-
tionary relationship with primate lentiviruses, at least in terms
of transactivation mechanism, and may be used as a model to
further dissect the molecular mechanism of Tat transactivation
and its role in the pathogenesis of lentivirus infections.
To further study the similarities and differences between the
JDV and the HIV Tat, we investigated the transactivation of
the HIV LTR by the JDV Tat. As expected, JDV Tat trans-
activated HIV LTR at least partially in a TAR-dependent
manner, and this may involve similar mechanisms and common
cellular factors in the two systems. Moreover, we demonstrated
that JDV Tat functionally substituted for the HIV Tat when
the JDV tat gene was introduced into the HIV genome. Our
study provides additional evidence that the JDV Tat is a potent
transactivator and indicates that further characterization of the
molecular mechanism involved in transactivation by JDV Tat is
warranted.
MATERIALS AND METHODS
Plasmids. Several HIV and JDV LTR promoter constructs were used in this
study. A series of HIV LTR mutants with deletions and mutations in the TAR
region of the LTR, TARCAT and Mod1CAT to Mod7CAT, were used. The
clone TARCAT, used as a positive control, contained the HIV 59 LTR region
(nucleotide [nt] 2121 to 182, encompassing the intact TAR sequence) cloned in
front of the indicator chloramphenicol acetyltransferase (CAT). Additional mu-
tant HIV LTR promoter constructs used were derivatives of TARCAT; these
were used previously to test their responsiveness to Tat transactivation (25). A
pHIV-CAT clone that contained the intact HIV U3R region was described
previously (35). The constructs pHTLV-CAT and pCMV-Tax were a kind gift
from Fatah Kashanchi (37). The mutant HIV Tat construct pDCys1-4 used was
described previously (26). The JDV promoter construct, pJU3R-CAT, was con-
structed as previously described (14); this clone was generated by insertion of the
CAT gene into a site 39 of the U3R region of the JDV LTR.
Various HIV and JDV tat expression constructs were generated using the
expression plasmid pUC-RSV. The pUC-RSV plasmid was generated by insert-
ing the Rous sarcoma virus LTR and the bovine growth hormone polyadenyla-
tion signal sequence from pRc/RSV (Invitrogen, Carlsbad, Calif.) into pUC18.
The HIV or the JDV tat exon 1 was PCR amplified and inserted into vector
pUC-RSV to generate pUC-Htat and pUC-Jtat, both of which encoded the
FIG. 2. Competitive inhibition of Tat-induced transactivation by the truncated Tat proteins. (A) CV-1 cells were cotransfected with 0.05 mg of pHIV-CAT, 0.1 mg
of HIV tat plasmid pUC-Htat, and the indicated amount of the competitors (pUC-J67 expresses the truncated JDV Tat protein and pUC-H50 expresses the truncated
HIV Tat protein). The indicated values represent the percentages of the amount of CAT in the presence of competitor relative to that in the absence of competitor
(defined as 100%). (B) CV-1 cells were cotransfected with 0.05 mg of pHIV-CAT plasmid, 0.25 mg of JDV tat plasmid pUC-Jtat, and the indicated amounts of
competitors. (C) CV-1 cells were cotransfected with 0.5 mg of pJU3R-CAT plasmid, 0.25 mg of JDV tat plasmid pUC-Jtat, and the indicated amounts of competitors.
(D) CV-1 cells were cotransfected with 0.15 mg of pHTLV-CAT plasmid, 0.1 mg of pCMV-Tax plasmid, and the indicated amounts of competitors. The total amount
of DNA used in each transfection was equalized with a control plasmid. Control in the figure represents no competitor addition.
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transactivation-competent Tat peptides. The truncated HIV tat (corresponding
to amino acids 1 to 50) and the truncated JDV tat sequences (corresponding to
amino acids 1 to 67) were cloned into pUC-RSV to generate plasmids pUC-H50
and pUC-J67. These two plasmids encoded truncated peptides which had lost
their transactivation abilities. Two tat mutant proviral clones, pMtat(2) and
pMtat30, were obtained from the AIDS Research and References Program
National Institute of Allergy and Infectious Diseases [NIAID], National Insti-
tutes of Health, Bethesda, Md.): pMtat(2) contains a termination codon (TGA)
in place of the ATG initiation codon and is unable to synthesize Tat (49);
pMtat30, which carries a Cys3Gly substitution within the cysteine-rich region,
produces a missense Tat (50).
The HIV infectious proviral clone pNL43 was obtained from the AIDS Re-
pository (NIAID) (1). This proviral clone was used to generate other modified
HIV proviral clones. The tat gene mutant pNL-tatm proviral plasmid was gen-
erated by introducing a stop codon into the tat gene of pNL43 using a PCR-based
mutagenesis method (5). This mutation was verified by EcoRI restriction enzyme
digestion, since a new EcoRI site was generated in the mutated tat gene (TGG
AAG CAT mutated to TGA ATT CAT). Using this plasmid, an NdeI restriction
site was introduced into the ATG site of the nef gene and was then used to
construct another modified proviral clone that carried the JDV tat gene. The
plasmid pNL-Jtat contained the JDV tat gene, in which the NdeI/XhoI fragment
of the nef gene of pNL-tatm was replaced by the JDV tat gene exon 1 sequences.
In addition, a random stretch of sequence (32 bp) was introduced into the nef
gene of pNL-tatm to generate pNL-nef, which was used as the negative control
in the various experiments. As a control, the plasmid Tat(2)1ex, which contains
the HIV tat in place of the nef gene, was constructed using a similar strategy (45),
and was kindly provided by K. T. Jeang (NIAID).
Transfection, virus stock, and CAT ELISA. CV-1, HeLa, and 293T cells were
maintained in Dulbecco’s modified Eagle’s medium with 10% fetal calf serum.
As described previously (11), 2 3 105 cells were seeded into 60-mm-diameter
dishes 24 h prior to transfection. The cells were transfected with 1 to 2 mg of
CsCl-purified plasmid DNA using Lipofectamine (GIBCO BRL, Grand Island,
N.Y.). At 48 h after transfection, the cells were harvested and lysed, and the
amount of protein in the lysate was determined using a bicinchoninic acid protein
assay kit (Pierce, Rockford, Ill.). For cells transfected with the promoter CAT
construct plasmids, the level of CAT expression was determined by a commercial
CAT enzyme-linked immunosorbent assay (ELISA) (Boehringer Mannheim,
Indianapolis, Ind.) according to the protocols described by the manufacturer.
Stocks of infectious virus were produced by transfection of cells with proviral
DNA. The medium from the transfected cells was collected 48 h posttransfec-
tion, the cells and cellular debris were removed by centrifugation, and the
supernatant was used as a source of infectious virus. The titer of virus was
measured by the p24 assay according to protocols described by the manufacturer
(NEN Life Sciences Products, Boston, Mass.).
Viral infection and p24 assays. Human peripheral blood mononuclear cells
(PBMC) were maintained in RPMI 1640 with 10% fetal bovine serum and IL-2
(2 U/ml) (Pharmacia, Piscataway, N.J.) and stimulated with phytohemagglutinin
(at a final concentration of 250 ng/ml) for 1 to 3 days prior to infection. For each
infection, 2 3 106 PBMC in a 0.5-ml volume were incubated with virus at 37°C
for 2 h. The virus-containing medium was then decanted and replaced with fresh
RPMI medium containing IL-2 (2 U/ml). The infected cultures were sampled
every 6 to 7 days, and the amount of virus produced was measured by p24 assay.
Sequence analysis. The alignment of Tat amino acid sequences was performed
using the Clustal W program in the GCG package (Madison, Wis.). Phylogenetic
reconstruction trees were generated using the Evolution program in the GCG
package. The Distance program (with Kimura’s formula) was used to generate a
pairwise matrix of the evolutionary distance of the amino acid sequences. Phy-
logenetic trees were constructed from the same distance matrices with the Grow-
tree program (neighbor-joining algorithm or unweighted pair group method with
averages [UPGMA]).
RESULTS
Transactivation of HIV LTR by JDV Tat is TAR dependent.
Our previous study demonstrated that JDV Tat was a potent
transactivator which could significantly increase the LTR-di-
rected gene expression of different animal and primate lenti-
viruses, including HIV (11, 14). We found that the JDV Tat
not only stimulated its own LTR significantly but also stimu-
lated HIV LTR-directed CAT expression to high levels equiv-
alent to those obtained with HIV Tat (11). The activation of
JDV LTR by JDV Tat was mediated by TAR-like elements
located in the LTR, and the loop region in the TAR seemed to
be less critical for JDV-mediated transactivation.
To further investigate the activation of HIV LTR by JDV
Tat and whether similar mechanisms of transactivation were
involved, a series of HIV TAR and LTR mutants were studied.
These constructs were generated previously (25) and consisted
of either deletions or mutations in the stem, the bulge, or the
loop region of the HIV TAR. These mutants are summarized
in Fig. 1A and were designated TARCAT, Mod1CAT,
Mod2CAT, Mod3CAT, Mod4CAT, Mod5CAT, Mod6CAT,
and Mod7CAT. Each plasmid construct was cotransfected into
CV-1 cells with the JDV tat expression plasmid, pUC-Jtat, and
tested for its ability to be activated by the JDV Tat (Fig. 1B).
TARCAT containing the intact TAR sequence was used as the
wild-type LTR. Mod7CAT, which contained the minimum
HIV TAR required for HIV Tat transactivation, showed wild-
type levels of transactivation in the presence of either JDV or
HIV Tat. The responsiveness of the remaining HIV LTR mu-
tants to transactivation by HIV Tat and JDV Tat was severely
impaired and varied. The mutants Mod1CAT, Mod2CAT,
Mod4CAT, and Mod6CAT, with mutations in the TAR stem
and bulge region, were activated by JDV Tat about 60 to 80%
FIG. 3. Complementation of the tat mutant HIV proviruses by JDV Tat and
HIV Tat. A 0.1-mg amount of tat mutant HIV proviral DNA was cotransfected
into CV-1 cells with varying concentrations of the JDV and HIV tat plasmids, as
indicated. The culture supernatant was collected at 72 h posttransfection, and the
amount of HIV produced was determined by p24 ELISA. (A) Complementation
of the HIV tat mutant clone pMtat(2) by JDV Tat and HIV Tat. This mutant
carries a termination codon in place of the ATG (methionine) initiator codon in
the Tat coding region (49). (B) Complementation of the HIV tat mutant clone
pMtat30 by JDV and HIV Tat. This mutant has a Cys3Gly substitution within
the Tat cysteine cluster and produces a missense Tat (50).
2706 CHEN ET AL. J. VIROL.
less than was the wild-type HIV LTR. However, we consis-
tently observed that these mutant promoters still responded
better to the JDV Tat than to the HIV Tat, even though the
activities were much lower than that with the wild-type LTR.
The Mod3CAT mutant, which had a 2-base substitution in the
loop region, retained most of its responsiveness to JDV Tat,
but not to HIV Tat. Mod5CAT, which had a 5-base insertion
in the loop region, was impaired in its ability to be activated
although it has a relatively higher basal level of promoter
activity. The data demonstrated that the JDV Tat transacti-
vated the HIV LTR at least partially in a TAR-dependent
manner, and sequences in the loop region of HIV LTR seemed
to be less important. The data further support our earlier
results that showed that activation of the JDV LTR by JDV
Tat did not involve the loop sequence of the TAR region (11).
JDV and HIV Tat activation of the LTR can be competitively
inhibited by coexpression of the HIV or JDV Tat activation
domain. HIV Tat has been shown to transactivate the LTR by
recruiting the cyclin T-CDK9 complex to the TAR region
which then phosphorylates the C-terminal domain of RNA
polymerase II (15, 32, 34, 47, 56). In comparing the JDV Tat
sequence with HIV Tat, we found that the JDV Tat contained
a very conserved cysteine-rich domain and a core domain,
which are both involved in the HIV Tat binding of cellular
factors. Therefore, it is likely that JDV Tat transactivates HIV
LTR by a similar mechanism and might involve similar cellular
factors.
We constructed two truncated tat plasmids, pUC-J67, which
encoded a JDV Tat peptide, JTat67 (amino acids 1 to 67), and
pUC-H50, which encoded an HIV Tat activation domain,
HTat50 (amino acids 1 to 50). We first examined the ability of
the expressed truncated Tat peptide JTat67 and HTat50 to
inhibit the transactivation function of HIV Tat and the effect of
intact JDV Tat on the HIV LTR (Fig. 2A and B). These
truncated proteins lost their abilities to transactivate HIV LTR
and JDV LTR and did not inhibit the basal level of LTR
expression (data not shown). We then cotransfected CV-1 cells
with the target plasmid pHIV-CAT, effector plasmid pUC-
Htat or pUC-Jtat, and varying concentrations of the competi-
tor plasmid pUC-H50 or pUC-J67 (Fig. 2A and B); the total
amount of DNA in each transfection was normalized by co-
transfection of the parent vector pUC18. As shown in Fig. 2A
and B, JTat67 and HTat50 efficiently inhibited transactivation
of the HIV LTR by both HIV Tat and JDV Tat, in a dose-
dependent manner. A 20-fold excess of the competitor plasmid
pUC-J67 or pUC-H50 inhibited HIV Tat activation of the HIV
LTR by about 65% (Fig. 2A), whereas a 10-fold excess of
pUC-J67 inhibited HIV Tat transactivation of the HIV LTR by
about 40% and a 10-fold excess of pUC-H50 resulted in a 50%
decrease in activity (Fig. 2A). However, when only a 2.5-fold
excess of competitor was added, the JDV peptide JTat67 was
ineffective while the HIV peptide inhibited activation about
30%. The inhibition of HIV LTR activation by JDV Tat was
similar (Fig. 2B): a 16-fold excess of either pUC-J67 or pUC-
H50 caused significant inhibition of HIV LTR activation, 40%
inhibition with pUC-J67 and 50% inhibition with pUC-H50;
lower concentrations of pUC-H50 seemed to cause greater
inhibition (Fig. 2B).
FIG. 4. Schematic representation of the wild-type pNL43 and the various modified virus genomes. The pNL-tatm was generated by introducing a stop codon at
amino acid 12 of the tat gene to render it inactive. This clone was then used to construct the other modified HIVs. pNL-Jtat express the JDV Tat exon 1 using the ATG
of the nef gene. pNL-nef contains a random sequence insertion in the nef gene. Tat(2)1ex was used and described previously (45).
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We next examined the effect of the truncated Tat proteins
on transactivation of the JDV LTR by JDV Tat (Fig. 2C).
Cotransfection of CV-1 cells with pJU3R-CAT, pUC-Jtat, and
varying concentrations of competitor plasmids (either pUC-
H50 or pUC-J67) inhibited JDV Tat transactivation to levels
similar to those observed with the HIV LTR. A 10-fold excess
of either of the Tat inhibitors HTat50 and JTat67 inhibited
activation by about 50%. At lower concentrations of the inhib-
itors, the HIV Tat truncated protein also seemed to be more
effective than the JDV truncated Tat protein. These results
demonstrated that both truncated JDV and HIV Tat may
inhibit transactivation by the intact Tat, possibly by competing
for common cellular factors used by both JDV and HIV Tat.
To confirm that the inhibition by the JDV and HIV Tat
activation domains was specific to Tat-mediated activation, we
also examined the effects of these activation domains on the
activation of human T-cell leukemia virus (HTLV) LTR by its
cognate transactivator Tax. The presence of either HIV or
JDV Tat transactivation domain did not dramatically affect the
activation of the HTLV LTR by Tax. However, a slight inhi-
bition by a fivefold or more excess of HIV Tat transactivation
domain expression plasmid pUC-H50 and a 10-fold or more
excess of JDV Tat transactivation domain expression plasmid
pUC-J67 was observed. These results suggested that the inhi-
bition effects of the JDV and HIV Tat activation domain were
Tat specific but may also have involved some nonspecific tran-
scription factors (Fig. 2D).
JDV Tat can complement HIV tat(2) provirus expression.
Tat is a potent and essential transcriptional transactivator of
HIV LTR, and HIV-1 proviruses mutated in tat are nonviable
(18, 49). However, this defect can be complemented by coex-
pression of the HIV Tat in trans. To determine whether JDV
Tat can also complement the HIV tat(2) provirus expression
in trans, two tat mutant HIV proviral plasmids, pMtat(2) and
pMtat30, were cotransfected into CV-1 cells with a JDV Tat
expression plasmid. Both tat mutants were demonstrated pre-
viously to be defective due to the mutations at the initiation
codon of the Tat protein or at the cysteine-rich transactivation
domain (49, 50). At 48 h posttransfection, supernatant was
collected and assayed for the expression of HIV by p24 anal-
ysis. It was determined that transfection of the two tat mutant
cDNA plasmids alone into CV-1 cells did not produce detect-
able levels of HIV as measured by p24 assays. However, in the
presence of either the JDV tat or the HIV tat plasmid, HIV
p24 was detected (Fig. 3). An increase in the amount of the
JDV or HIV Tat plasmid transfected resulted in higher levels
of HIV production. Our results demonstrated that both tat
HIV mutants were complemented equally well by the presence
of JDV or HIV Tat. This complementation assay demon-
strated that the JDV Tat could functionally complement the
defect in the tat gene in the HIV provirus to enable the rep-
lication of HIV in the proviral DNA-transfected cell.
Construction and characterization of chimeric HIV carrying
the JDV tat gene. To further investigate whether JDV tat could
functionally substitute for the HIV tat gene, we constructed a
chimeric proviral clone by inserting the JDV tat gene into HIV
proviral backbone, pNL43 (Fig. 4). To avoid affecting the func-
tion of other genes which overlap with the tat gene, we intro-
duced a stop codon into the tat region of the HIV proviral
plasmid pNL43 to inactivate tat, and an EcoRI site was gen-
erated in the mutated tat region. The resulting plasmid, pNL-
tatm, with a tat mutation, otherwise isogenic to pNL43, was
wild type in all other genes. A chimeric pNL-Jtat virus was also
constructed, wherein a small fragment of nef was replaced with
cDNA coding for JDV Tat exon 1 but still using the native nef
ATG translation initiation site. The pNL43 nef could be effec-
tively replaced since such nef mutations do not significantly
affect the in vitro replication and infectivity of the mutant HIV
in T-cell lines (45). As a positive control, a chimeric virus,
Tat(2)1ex, containing the HIV exon 1 tat, was constructed
using a similar strategy (45). A pNL-nef plasmid, in which
random sequences were inserted into the nef region of pNL-
tatm to further inactivate nef, was used as a negative control.
We first characterized the ability of these modified proviral
clones to replicate and generate viruses in transfected cells.
When 1 mg of the above plasmids was transfected into non-
permissive cells such as CV-1, HeLa, and 293T cells, the tat
mutant proviral clones pNL-tatm and pNL-nef did not produce
detectable levels of HIV in HeLa cells and produced much
lower levels of HIV in 293T and CV-1 cells than did wild-type
virus pNL43 (Table 1). In contrast, Tat(2)1ex and pNL-Jtat,
which contain the HIV tat and JDV tat, respectively, produced
wild-type levels of expression of HIV in all the tested cell lines.
To rule out the possibility that the failure to express virus in
cells transfected with pNL-tatm or pNL-nef was due to other
unexpected defects besides the tat mutation in the genome, we
cotransfected these cells with tat mutant proviral DNAs and
either JDV or HIV Tat-expressing plasmids. For both pNL-
tatm and pNL-nef, in the presence of HIV or JDV tat, the
replication of the viruses in the transfected cells was restored
and high levels of p24 were detected in the culture supernatant.
Cotransfection of Tat-expressing plasmids with Tat(2)1ex, pNL-
Jtat, or pNL43 proviral DNA only slightly increased or did not
change the level of HIV expression. Cotransfection of a mu-
tant HIV Tat-expressing plasmid, pDCys1-4, which carries four
Cys3Ser amino acid substitutions in the Cys-rich region and
has lost its transactivation ability, failed to rescue the tat-de-
fective virus (Table 1).
TABLE 1. p24 assay of supernatant from chimeric proviral
DNA-transfected cellsa
Plasmid(s)







pNL43 636.5 21.8 .1,000.0
pNL43 1 pUC-Jtat .600.0 16.3 1,063.9
pNL43 1 pUC-Htat 625.3 19.9 1,064.8
pNL43 1 pDCys1-4 ND 20.6 ND
pNL-tatm 5.8 1.3 267.8
pNL-tatm 1 pUC-Jtat .600.0 15.8 .1,000.0
pNL-tatm 1 pUC-Htat .600.0 20.6 1,105.6
pNL-tatm 1 pDCys1-4 ND 0.7 ND
pNL-nef 1.2 0.6 77.4
pNL-nef 1 pUC-Jtat 177.7 18.2 1,005.6
pNL-nef 1 pUC-Htat 638.2 15.7 885.2
pNL-nef 1 pDCys1-4 ND 0.05 ND
pNL-Jtat 605.7 12.6 1,122.1
pNL-Jtat 1 pUC-Jtat .600.0 11.3 1,132.1
pNL-Jtat 1 pUC-Htat 645.7 13.3 1,137.8
pNL-Jtat 1 pDCys1-4 ND 8.5 ND
Tat(2)1ex 650.2 13.4 1,058.6
Tat(2)1ex 1 pUC-Jtat .600.0 8.9 1,160.4
Tat(2)1ex 1 pUC-Htat .600.0 8.4 .1,000.0
Tat(2)1ex 1 pDCys1-4 ND 3.4 ND
a One microgram of proviral DNA was transfected into either HeLa, 293T, or
CV-1 cells with or without tat plasmids. At 48 h posttransfection, the superna-
tants were collected and assayed for p24 production. ND, not determined.
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To further determine whether the presence of JDV tat in the
chimeric virus could fully complement the HIV tat functions
and enable the virus to productively infect CD41 T cells, the
viruses generated by transfection were used to infect both
primary PBMC and a T-cell line, C8166 (45). The amount of
virus produced from the transfected 293T cells was determined
by p24 antigen levels, a similar amount of virus from each
transfection experiment was then used to infect both fresh
PBMC and C8166 cells, and the infected cells were monitored
for virus growth by p24 assay at various time points after
infection (Fig. 5A). The control chimeric virus Tat(2)1ex, con-
taining the HIV tat gene, replicated in the T-cell line as dem-
onstrated previously (45). The NL-Jtat virus, containing JDV
tat, also replicated efficiently in this T-cell line, and substantial
amounts of p24 were detected 14 days after infection. Almost
twice as much p24 was detected in NL-Jtat-infected cells as in
those infected by the control Tat(2)1ex virus. Our results thus
showed that the chimeric virus with the HIV tat replaced by the
JDV tat was fully competent in its ability to infect and replicate
in C8166 T cells. As expected, the negative control viruses,
NL-tatm and NL-nef, did not replicate.
To further characterize the chimeric viruses, their ability to
infect and replicate in primary T cells was tested. It was pre-
viously shown that the HIV chimera with the HIV nef gene
replaced by HIV tat was unable to replicate in PBMC (45),
suggesting that either the HIV tat exon 1 alone or the destruc-
tion of the HIV nef affected the ability of HIV to replicate in
primary cells. Indeed, when we tested our various chimeric
viruses in PBMC (Fig. 5B), the Tat(2)1ex virus containing the
HIV tat exon 1 did not replicate in PBMC even though it
replicated in C8166 cells, similar to results obtained previously
with this virus (45). In contrast, the chimeric NL-Jtat which
FIG. 5. Growth and replication kinetics of the various recombinant HIV-1 viruses in the C8166 T-cell line and PBMC. (A) Different viral stocks generated by
transfection of 293T cells were used to infect the C8166 T-cell line. The 293T cells were transfected with the recombinant proviral DNA using Lipofectamine. At 48 h
posttransfection, supernatants were collected, and the p24 levels were determined. C8166 cells (2 3 105) were infected by 10 ng of the different viruses as determined
by the p24 assay. The amount of virus produced was monitored at the indicated time points by p24 analysis. The cross in the figure represents a p24 concentration of
103 ng/ml, which is beyond the y-axis scale. (B) PBMC (2 3 106) were infected with 10 ng of virus as determined by the p24 assay, and the amount of virus produced
was monitored at the indicated time points as described above.
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contained the JDV tat infected and replicated effectively in the
primary PBMC, even though the levels seemed to be lower
than those of the wild-type virus NL43. It produced lower
levels of virus expression initially, but by 14 days the levels
seemed to have increased and by 18 days were much higher.
Our results suggested that the presence of JDV exon 1 tat
complemented both HIV tat and nef to render the virus fully
replication competent in both PBMC and T-cell lines. As ex-
pected, both tat mutant virus NL-tatm and NL-nef failed to
replicate in PBMC.
To rule out the possibility that infection of PBMC and
C8166 cells by chimeric virus NL-Jtat was due to the back
mutation of the HIV tat mutation to wild type, the HIV tat
gene of the infected cells was analyzed by PCR and restriction
analysis of the infected PBMC viral DNA (Fig. 6). Since the
mutated tat gene was engineered to have an EcoRI site, the
presence of the restriction site would indicate persistence of
the mutation. Indeed, the amplified tat gene product from the
chimeric virus NL-Jtat-infected cellular DNA, but not the wild-
type virus-infected cellular DNA, was cut completely by EcoRI
to generate a smaller tat gene fragment of the expected size
(Fig. 6A, compare lanes 1 and 4). This result suggested that the
mutation in the tat gene for NL-Jtat persisted and that rever-
sion to the wild type was not responsible for the ability of this
virus to replicate in PBMC. To further confirm that the JDV
and HIV tat gene insertion in the nef region had not been
deleted, the nef region of the viruses from the infected PBMC
was analyzed by PCR. As was expected, the PCR-amplified
fragments from NL-Jtat and Tat(2)1ex viruses were relatively
larger than the wild-type nef fragment, indicating that the tat
insert was retained (Fig. 6B).
Phylogenetic analysis of lentivirus Tat proteins. The cross-
transactivation by JDV Tat of the HIV LTR suggested a close
evolutionary relationship between JDV and other primate len-
tiviruses. To analyze the evolutionary genetic relationship be-
tween JDV and other lentiviruses, a neighbor-joining phyloge-
netic tree based on the published sequences of lentiviral Tat
peptides which are competent in transactivation was con-
structed (3, 11, 17, 20, 21, 36, 41, 51, 52, 55) (Fig. 7A). With the
constructed tree, two major subgroups of Tat were formed
(primate versus nonprimate lentivirus Tat proteins). Within
the primate lentivirus subgroup, the simian immunodeficiency
virus Tat was more closely related to HIV-2 Tat than to HIV-1
Tat. Within the nonprimate lentivirus Tat group, the JDV and
BIV Tat proteins were closely related phylogenetically. Inter-
estingly, the two bovine lentivirus Tat proteins were more
closely related to the primate lentivirus Tat proteins than they
were to the nonprimate lentivirus Tat proteins. Another phy-
logenetic tree created by using UPGMA also showed a similar
phylogenetic relationship, and although no distinctive nonpri-
mate lentiviral Tat subgroup was formed with this method of
analysis (Fig. 7B), JDV and BIV Tat proteins were within a
subgroup which mainly contained the primate lentivirus Tat
proteins.
DISCUSSION
A comparison of the amino acid sequences of the JDV and
HIV Tat showed a striking homology in the cysteine-rich and
the core activation domain, but very little similarity in the RNA
binding basic domain (11). Indeed, competitors containing the
HIV-1 and JDV Tat activation domain could inhibit the HIV
and JDV Tat transactivation of the HIV LTR or the JDV Tat
transactivation of the JDV LTR. Since both truncated proteins
did not contain the basic RNA binding domain that is respon-
sible for the TAR binding, the inhibition was unlikely to be due
to competition for binding to TAR and more likely was due to
the effects of the transactivating domain itself. These observa-
tions support the notion that the JDV and HIV Tat activation
domains may involve a similar transactivation mechanism and
both may involve interaction with cellular cofactors. The cross-
inhibition of Tat functions may be due to the sequestering of
the cellular factors involved.
In this study, we have demonstrated that the transactivation
effect of JDV Tat on HIV LTR is at least partially TAR
dependent. Mutations of TAR in the HIV LTR, except for
mutations in the loop region as represented by mutant
Mod3CAT, resulted in significant loss of responsiveness to
JDV Tat transactivation. However, differences in the Tat of
JDV and HIV were noted. First, as the HIV LTR mutant
Mod3CAT was responsive to transactivation by JDV Tat but
not to that by HIV Tat, this suggested that a sequence in the
loop region of HIV TAR was not critical for transactivation by
JDV Tat but was essential for transactivation by HIV Tat.
Second, most HIV LTR mutants retained some responsiveness
to the JDV Tat even though they were not activated by HIV
Tat. These differences could be due to the JDV Tat transacti-
vating the HIV LTR using other mechanisms in addition to the
TAR-dependent pathway, or the JDV Tat-TAR interaction
FIG. 6. PCR analysis of the viruses generated from the infected PBMC
cultures. The figure shows PCR amplification of tat and nef gene sequences from
the infected PBMC cellular DNA. At 18 days after infection, PBMC cellular
DNA was extracted from cells infected with different viruses, and PCR amplifi-
cation with the appropriate primers was performed. (A) Verification of tat
mutation in the recombinant virus by EcoRI digestion. PCR products of the tat
region amplified from infected PBMC DNA were purified from 1% agarose gels
and then cut with EcoRI. To avoid amplification of the inserted tat sequences in
the recombinant virus, the primers NL-tat1 (nt 5762 to 5781, 59 GTT TAT CCA
TTT CAG AAT TG 39) and NL-tat2 (nt 6428 to 6409, 59 CCA AAC ATT ATG
TAC CTC TG 39) used were located outside the tat sequences (nt 5830 to 6044)
in the NL43 genome (GenBank accession no. M19921). Lane 1, NL43 virus tat
DNA; lane 2, Tat(2)1ex virus tat DNA; lane 3, NL-tatm virus tat DNA; lane 4,
NL-Jtat virus tat DNA. (B) PCR amplification of nef sequences from the infected
PBMC DNA to verify the presence of the tat insert in the nef region of the
recombinant virus genome. PCR was performed with primers NL-nef1 (nt 8447
to 8465, 59 TCC ATT CGA TTA GTG AAC G39) and NL-nef2 (nt 8904 to 8886,
59 CTA CTT GTG ATT GCT CCA T39). Lane 1, lambda/HindIII; lane 2, NL43;
lane 3, Tat(2)1ex; lane 4, NL-tatm; lane 5, NL-nef, lane 6, NL-Jtat; lane 7,
mock-infected control. wt, wild type.
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may be different from the HIV Tat-TAR interaction. We favor
the latter explanation, since our results suggest that the loop
sequence in the TAR is not critical for JDV transactivation,
which is different from that by HIV. Studies of HIV have
shown that the loop region is the binding site for cyclin T, and
the binding of cyclin T to the loop can significantly stabilize the
HIV Tat-TAR interaction (56). Recent data have convincingly
demonstrated that the binding of the HIV Tat activation do-
main to the cyclin T1 subunit of the human TAK/P-TEFb
transcription elongation complex is a critical first step in TAR
RNA recognition and Tat-mediated transactivation (32). It is
possible that JDV Tat can directly interact with the TAR
elements independent of cyclin T complex binding, and thus
the mutations of the cyclin target in the loop region would not
affect the transactivation function of the JDV Tat. However,
this does not exclude the possibility that the cyclin T complex
is still involved in the JDV Tat-induced transactivation of the
HIV LTR. Further studies are necessary in order to decipher
the role of cyclin T in JDV Tat transactivation.
In addition to a transactivation function, Tat is essential for
viral replication and pathogenesis (12, 18, 45, 62). HIV Tat was
reported to activate quiescent T lymphocytes and induce apo-
ptosis (38, 40) and may contribute to the selective depletion of
CD41 lymphocytes in vivo. Tat is also vital for viral replication
and infection; mutations in tat led to viruses that were defective
(3, 4). Relocation of tat in the HIV genome or the substitution
of HIV tat for the nef gene still led to viruses that were defec-
tive; they were able to replicate in T-cell lines but not in PBMC
(45). Substitution for the HIV tat by alternative transactivators,
such as HTLV Tax and Vp16, which were cloned into HIV
tat(2) has resulted in viruses that replicate very poorly in
PBMC and other cell types (45). Our chimeric virus that used
JDV tat exon 1 is therefore unique, as JDV tat exon 1 was able
to substitute for HIV tat and enable successful replication in
both a T-cell line and PBMC, even though resulting virus
replication was less than that with the wild-type virus. Our
results indicated that JDV Tat can functionally replace HIV
Tat and suggest that JDV Tat should play a role in viral
replication and pathogenesis of infection similar to that of HIV
Tat in HIV. In addition, the JDV Tat could rescue a mutant
HIV when it was mutated not only in the tat but also in the nef
gene, suggesting that JDV Tat can substitute for both HIV Tat
and Nef to enable the virus to replicate effectively in vitro.
However, it is possible that this HIV-JDV chimeric virus may
be nonpathogenic and attenuated in vivo. Further character-
ization of this virus and its pathogenicity will be important not
only for elucidation of the functions of Tat but also for vaccine
development if the HIV-JDV chimeric virus is found to be
attenuated.
ACKNOWLEDGMENTS
This study was supported in part by the University of Nebraska
Center of Biotechnology Area of Concentration grant to C.W.
We thank K. T. Jeang for kindly providing the plasmid Tat(2)1ex,
R. Gaynor for plasmid pDCys1-4, and F. Kashanchi for plasmids
pHTLV-CAT and pCMV-Tax. The plasmids pMtat(2) and pMtat30
were obtained through the AIDS Research and Reference Reagent
Program from Reza Sadaie. We also thank Malcolm Martin for pro-
viding the pNL43 plasmid through the AIDS Research and Reference
Reagent Program.
REFERENCES
1. Adachi, A., S. Koenig, H. E. Gendelman, D. Daugherty, S. Gattoni-Celli,
A. S. Fauci, and M. A. Martin. 1987. Productive, persistent infection of
human colorectal cell lines with human immunodeficiency virus. J. Virol.
61:209–213.
FIG. 7. Phylogenetic analysis of the various lentivirus Tat proteins. The Tat amino acid sequences were deduced from the tat nucleotide sequences: JDV genome
(GenBank accession no. U21603), BIV (GenBank accession no. M32690), HIV-1 (GenBank locus hivhxb2cg), HIV-2 (GenBank accession no. M38432), simian
immunodeficiency virus (SIV) (GenBank accession no. M19499), equine infectious anemia virus (EIAV) (GenBank accession no. M30138), caprine arthritis-
encephalitis virus (CAEV) (GenBank accession no. M34092), feline immunodeficiency virus (FIV) (GenBank accession no. M36968), and visna virus tat sequence
(accession no. J04359). The trees were reconstructed using two separate programs as described in Materials and Methods. Phylogenetic analysis used the Evolution
program in GCG. (A) Analysis using the neighbor-joining algorithm; (B) analysis using the UPGMA algorithm.
VOL. 74, 2000 JDV Tat CAN REGULATE HIV LTR-DIRECTED GENE EXPRESSION 2711
2. Albini, A., G. Barillari, R. Benelli, R. C. Gallo, and B. Ensoli. 1995. Angio-
genic properties of human immunodeficiency virus type 1 Tat protein. Proc.
Natl. Acad. Sci. USA 92:4838–4842.
3. Arya, S. K., B. Beaver, L. Jagodzinski, B. Ensoli, P. J. Kanki, J. Albert, E. M.
Fenyo, G. Biberfeld, J. F. Zagury, F. Laure, M. Essex, E. Norrby, F. Wong-
Staal, and R. C. Gallo. 1987. New human and simian HIV-related retrovi-
ruses possess functional transactivator (tat) gene. Nature 328:548–550.
4. Arya, S. K., C. Guo, S. F. Josephs, and F. Wong-Staal. 1985. Trans-activator
gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69–73.
5. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A.
Smith, and K. Struhl (ed.). 1989. Current protocols in molecular biology.
Greene Publishing Associates, New York, N.Y.
6. Barillari, G., R. Gendelman, R. C. Gallo, and B. Ensoli. 1993. The Tat
protein of human immunodeficiency virus type 1, a growth factor for AIDS
Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of
the same cell types by using integrin receptors recognizing the RGD amino
acid sequence. Proc. Natl. Acad. Sci. USA 90:7941–7945.
7. Budiarso, I. T., and S. Hardjosworo. 1976. Jembrana disease in Bali cattle.
Aust. Vet. J. 52:97.
8. Buonaguro, L., G. Barillari, H. K. Chang, C. A. Bohan, V. Kao, R. Morgan,
R. C. Gallo, and B. Ensoli. 1992. Effects of the human immunodeficiency
virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol.
66:7159–7167.
9. Chadwick, B. J., R. J. Coelen, L. M. Sammels, G. Kertayadnya, and G. E.
Wilcox. 1995. Genomic sequence analysis identifies Jembrana disease virus
as a new bovine lentivirus. J. Gen. Virol. 76:189–192.
10. Chadwick, B. J., R. J. Coelen, G. E. Wilcox, L. M. Sammels, and G. Ker-
tayadnya. 1995. Nucleotide sequence analysis of Jembrana disease virus: a
bovine lentivirus associated with an acute disease syndrome. J. Gen. Virol.
76:1637–1650.
11. Chen, H., G. E. Wilcox, G. Kertayadnya, and C. Wood. 1999. Characteriza-
tion of the Jembrana disease virus tat gene and the cis- and trans-regulatory
elements in its long terminal repeats. J. Virol. 73:658–666.
12. Cheng-Mayer, C., T. Shioda, and J. A. Levy. 1991. Host range, replicative,
and cytopathic properties of human immunodeficiency virus type 1 are de-
termined by very few amino acid changes in Tat and gp120. J. Virol. 65:
6931–6941.
13. Clements, J. E., and M. C. Zink. 1996. Molecular biology and pathogenesis
of animal lentivirus infections. Clin. Microbiol. Rev. 9:100–117.
14. Coffin, J. M., S. H. Hughes, and H. E. Varmus. 1997. Retroviruses, p.
475–636. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
15. Cullen, B. R. 1998. HIV-1 auxiliary proteins: making connections in a dying
cell. Cell 93:685–692.
16. Cullen, B. R. 1995. Regulation of HIV gene expression. AIDS 9:S19–32.
17. Davis, J. L., and J. E. Clements. 1989. Characterization of a cDNA clone
encoding the visna virus transactivating protein. Proc. Natl. Acad. Sci. USA
86:414–418.
18. Dayton, A. I., J. G. Sodroski, C. A. Rosen, W. C. Goh, and W. A. Haseltine.
1986. The trans-activator gene of the human T cell lymphotropic virus type
III is required for replication. Cell 44:941–947.
19. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J.
Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson,
S. Crowe, D. Dowton, and J. Mills. 1995. Genomic structure of an attenuated
quasi species of HIV-1 from a blood transfusion donor and recipients.
Science 270:988–991.
20. de Parseval, A., and J. H. Elder. 1999. Demonstration that orf2 encodes the
feline immunodeficiency virus transactivating (Tat) protein and character-
ization of a unique gene product with partial Rev activity. J. Virol. 73:608–
617.
21. Dorn, P., L. DaSilva, L. Martarano, and D. Derse. 1990. Equine infectious
anemia virus tat: insights into the structure, function, and evolution of len-
tivirus trans-activator proteins. J. Virol. 64:1616–1624.
22. Ensoli, B., R. Gendelman, P. Markham, V. Fiorelli, S. Colombini, M.
Raffeld, A. Cafaro, H. K. Chang, J. N. Brady, and R. C. Gallo. 1994. Synergy
between basic fibroblast growth factor and HIV-1 Tat protein in induction of
Kaposi’s sarcoma. Nature 371:674–680.
23. Ensoli, B., G. Barillari, S. Z. Salahuddin, R. C. Gallo, and F. Wong-Staal.
1990. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s
sarcoma lesions of AIDS patients. Nature 345:84–86.
24. Ensoli, B., L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendelman, R. A.
Morgan, P. Wingfield, and R. C. Gallo. 1993. Release, uptake, and effects of
extracellular human immunodeficiency virus type 1 Tat protein on cell
growth and viral transactivation. J. Virol. 67:277–287.
25. Fong, S. E., P. Smanik, T. Thais, M. C. Smith, and S. R. Jaskunas. 1997.
Detection of specific human immunodeficiency virus type 1 Tat-TAR com-
plexes in the presence of mild denaturing conditions. J. Virol. Methods
66:91–101.
26. Garcia, J. A., D. Harrich, L. Pearson, R. Mitsuyasu, and R. B. Gaynor. 1988.
Functional domains required for tat-induced transcriptional activation of the
HIV-1 long terminal repeat. EMBO J. 7:3143–3147.
27. Harrich, D., C. Ulich, L. F. Garcia-Martinez, and R. B. Gaynor. 1997. Tat is
required for efficient HIV-1 reverse transcription. EMBO J. 16:1224–1235.
28. Harrich, D., C. Ulich, and R. B. Gaynor. 1996. A critical role for the TAR
element in promoting efficient human immunodeficiency virus type 1 reverse
transcription. J. Virol. 70:4017–4027.
29. Harrich, D., G. Mavankal, A. Mette-Snider, and R. B. Gaynor. 1995. Human
immunodeficiency virus type 1 TAR element revertant viruses define RNA
structures required for efficient viral gene expression and replication. J. Vi-
rol. 69:4906–4913.
30. Howcroft, T. K., K. Strebel, M. A. Martin, and D. S. Singer. 1993. Repression
of MHC class I gene promoter activity by two-exon Tat of HIV. Science
260:1320–1322.
31. Huang, L. M., A. Joshi, R. Willey, J. Orenstein, and K. T. Jeang. 1994.
Human immunodeficiency viruses regulated by alternative trans-activators:
genetic evidence for a novel non-transcriptional function of Tat in virion
infectivity. EMBO J. 13:2886–2896.
32. Ivanov, D., Y. T. Kwak, E. Nee, J. Guo, L. F. Garcia-Martinez, and R. B.
Gaynor. 1999. Cyclin T1 domains involved in complex formation with Tat
and TAR RNA are critical for tat-activation. J. Mol. Biol. 288:41–56.
33. Iversen, A. K., E. G. Shpaer, A. G. Rodrigo, M. S. Hirsch, B. D. Walker,
H. W. Sheppard, T. C. Merigan, and J. I. Mullins. 1995. Persistence of
attenuated rev genes in a human immunodeficiency virus type 1-infected
asymptomatic individual. J. Virol. 69:5743–5753.
34. Jeang, K. T. 1998. Tat, Tat-associated kinase, and transcription. J. Biomed.
Sci. 5:24–27.
35. Jung, M., and C. Wood. 1991. Activation of retroviral promoters by trans-
acting factors. Virology (Life Sci. Adv.) 10:77–88.
36. Kalinski, H., P. Mashiah, D. Rotem, Y. Orzech, L. Sherman, T. Miki, A.
Yaniv, A. Gazit, and S. R. Tronick. 1994. Characterization of cDNA species
encoding the Tat protein of caprine arthritis encephalitis virus. Virology
204:828–834.
37. Kashanchi, F., J. F. Duvall, P. F. Lindholm, M. F. Radonovich, and J. N.
Brady. 1993. Sequences downstream of the RNA initiation site regulate
human T-cell lymphotropic virus type I basal gene expression. J. Virol.
67:2894–2902.
38. Katsikis, P. D., M. E. Garcia-Ojeda, J. F. Torres-Roca, D. R. Greenwald, and
L. A. Herzenberg. 1997. HIV type 1 Tat protein enhances activation—but not
Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals.
Int. Immunol. 9:835–841.
39. Kirchhoff, F., P. J. Easterbrook, N. Douglas, M. Troop, T. C. Greenough, J.
Weber, S. Carl, J. L. Sullivan, and R. S. Daniels. 1999. Sequence variations
in human immunodeficiency virus type 1 nef are associated with different
stages of disease. J. Virol. 73:5497–5508.
40. Li, C. J., D. J. Friedman, C. Wang, V. Metelev, and A. B. Pardee. 1995.
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.
Science 268:429–431.
41. Liu, Z. Q., D. Sheridan, and C. Wood. 1992. Identification and character-
ization of the bovine immunodeficiency-like virus tat gene. J. Virol. 66:5137–
5140.
42. Mariani, R., F. Kirchhoff, T. C. Greenough, J. L. Sullivan, R. C. Desrosiers,
and J. Skowronski. 1996. High frequency of defective nef alleles in a long-
term survivor with nonprogressive human immunodeficiency virus type 1
infection. J. Virol. 70:7752–7764.
43. McCloskey, T. W., M. Ott, E. Tribble, S. A. Khan, S. Teichberg, M. O. Paul,
S. Pahwa, E. Verdin, and N. Chirmule. 1997. Dual role of HIV Tat in
regulation of apoptosis in T cells. J. Immunol. 158:1014–1019.
44. Michael, N. L., G. Chang, L. A. d’Arcy, P. K. Ehrenberg, R. Mariani, M. P.
Busch, D. L. Birx, and D. H. Schwartz. 1995. Defective accessory genes in a
human immunodeficiency virus type 1-infected long-term survivor lacking
recoverable virus. J. Virol. 69:4228–4236.
45. Neuveut, C., and K. T. Jeang. 1996. Recombinant human immunodeficiency
virus type 1 genomes with tat unconstrained by overlapping reading frames
reveal residues in Tat important for replication in tissue culture. J. Virol.
70:5572–5581.
46. Nowak, M. A., R. M. Anderson, M. C. Boerlijst, S. Bonhoeffer, R. M. May,
and A. J. McMichael. 1996. HIV-1 evolution and disease progression. Sci-
ence 274:1008–1011.
47. Parada, C. A., and R. G. Roeder. 1996. Enhanced processivity of RNA
polymerase II triggered by Tat-induced phosphorylation of its carboxyl-
terminal domain. Nature 384:375–378.
48. Pocsik, E., M. Higuchi, and B. B. Aggarwal. 1992. Down-modulation of cell
surface expression of p80 form of the tumor necrosis factor receptor by
human immunodeficiency virus-1 Tat gene. Lymphokine Cytokine Res. 11:
317–325.
49. Sadaie, M. R., T. Benter, and F. Wong-Staal. 1988. Site-directed mutagenesis
of two trans-regulatory genes (tat-III, trs) of HIV-1. Science 239:910–913.
50. Sadaie, M. R., J. Rappaport, T. Benter, S. F. Josephs, R. Willis, and F.
Wong-Staal. 1988. Missense mutations in an infectious human immunode-
ficiency viral genome: functional mapping of tat and identification of the rev
splice acceptor. Proc. Natl. Acad. Sci. USA 85:9224–9228.
51. Sakuragi, J., S. Sakuragi, S. Ueda, and A. Adachi. 1996. Functional analysis
of simian immunodeficiency virus SIVAGM long terminal repeat. Virus
Genes 12:21–25.
52. Saltarelli, M. J., R. Schoborg, S. L. Gdovin, and J. E. Clements. 1993. The
2712 CHEN ET AL. J. VIROL.
CAEV tat gene trans-activates the viral LTR and is necessary for efficient
viral replication. Virology 197:35–44.
53. Scala, G., M. R. Ruocco, C. Ambrosino, M. Mallardo, V. Giordano, F.
Baldassarre, E. Dragonetti, I. Quinto, and S. Venuta. 1994. The expression
of the interleukin 6 gene is induced by the human immunodeficiency virus 1
Tat protein. J. Exp. Med. 179:961–971.
54. Taylor, J. P., C. Cupp, A. Diaz, M. Chowdhury, K. Khalili, S. A. Jimenez, and
S. Amini. 1992. Activation of expression of genes coding for extracellular
matrix proteins in Tat-producing glioblastoma cells. Proc. Natl. Acad. Sci.
USA 89:9617–9621.
55. Viglianti, G. A., and J. I. Mullins. 1988. Functional comparison of transac-
tivation by simian immunodeficiency virus from rhesus macaques and human
immunodeficiency virus type 1. J. Virol. 62:4523–4532.
56. Wei, P., M. E. Garber, S. M. Fang, W. H. Fischer, and K. A. Jones. 1998. A
novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and
mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451–
462.
57. Weiss, R. A. 1993. How does HIV cause AIDS? Science 260:1273–1279.
58. Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H.
Walczak, K. M. Debatin, and P. H. Krammer. 1995. Sensitization of T cells
to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497–500.
59. Westendorp, M. O., M. Li-Weber, R. W. Frank, and P. H. Krammer. 1994.
Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secre-
tion in activated T cells. J. Virol. 68:4177–4185.
60. Wilcox, G. E., B. J. Chadwick, and G. Kertayadnya. 1995. Recent advances
in the understanding of Jembrana disease. Vet. Microbiol. 46:249–255.
61. Wilcox, G. E., S. Soeharsono, D. M. N. Dharma, and J. W. Copland. 1997.
Jembrana disease and the bovine lentiviruses. ACIAR Proc. 75:10–75.
62. Zagury, J. F., A. Sill, W. Blattner, A. Lachgar, H. Le Buanec, M. Richardson,
J. Rappaport, H. Hendel, B. Bizzini, A. Gringeri, M. Carcagno, M. Cris-
cuolo, A. Burny, R. C. Gallo, and D. Zagury. 1998. Antibodies to the HIV-1
Tat protein correlated with nonprogression to AIDS: a rationale for the use
of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1:282–292.
VOL. 74, 2000 JDV Tat CAN REGULATE HIV LTR-DIRECTED GENE EXPRESSION 2713
